Target, Home Depot,...
Health Care: Drugs
DepoMed Inc. (DEPO: NASDAQ)
$5.48 0.08 | 1.48%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 90.82M | 132.97M | 80.76M | 57.73M |
| Cost of Sales | 5.17M | 5.12M | 7.66M | 4.45M |
| Gross Operating Profit | 85.65M | 127.85M | 73.11M | 53.28M |
| Selling, General, and Administrative Expenses | 97.65M | 54.20M | 17.51M | 16.66M |
| Research & Development | 15.46M | 15.19M | 20.11M | 34.30M |
| Operating Income before D & A (EBITDA) | -27.46M | 31.12M | 4.06M | -21.26M |
| Depreciation & Amortization | 2.89M | 420.00K | 439.00K | 808.00K |
| Interest Income | 520.00K | 557.00K | 839.00K | 1.05M |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 40.00M | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -29.83M | 71.26M | 4.46M | -21.02M |
| Interest Expense | 39.00K | 133.00K | 572.00K | 1.00M |
| Pre-Tax Income | -29.87M | 71.12M | 3.89M | -22.02M |
| Income Taxes | -91.00K | 396.00K | -4.00K | -15.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -29.78M | 70.73M | 3.90M | -22.01M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -29.78M | 70.73M | 3.90M | -22.01M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -29.78M | 70.73M | 3.90M | -22.01M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-29.78M | 30.73M | 3.90M | -22.01M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -29.78M | 70.73M | 3.90M | -22.01M |
| Basic EPS from Continuing Ops. | -0.53 | 1.30 | 0.07 | -0.43 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.53 | 1.30 | 0.07 | -0.43 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.53 | 1.30 | 0.07 | -0.43 |
| Basic Normalized Net Income/Share | -0.53 | 0.56 | 0.07 | -0.43 |
| EPS fr Continuing Ops. | -0.53 | 1.26 | 0.07 | -0.43 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.53 | 1.26 | 0.07 | -0.43 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.53 | 1.26 | 0.07 | -0.43 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.53 | 0.55 | 0.07 | -0.43 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
Latest DEPO Headlines from TheStreet
- Short Interest In DepoMed Moves 11% Lower 04.25.13 | 04:04 pm
- Top 10 Trending On StockTwits At The Close (March 4) 03.04.13 | 06:03 pm
- Depomed FDA Panel Live Blog 03.04.13 | 07:03 am
- Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta 03.01.13 | 06:03 am
- The Next Big Thing In Biotech: DepoMed
02.28.13 | 09:02 am - Depomed Inc. Stock Upgraded (DEPO) 02.22.13 | 04:02 am
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Depomed Bear Case: FDA Panel Will Ding Serada 02.04.13 | 08:02 am
- Stocks Under $5: Stealth Healthcare Play 12.19.12 | 11:12 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
Press Releases for DEPO
- Depomed To Present At UBS Global Healthcare Conference - PR Newswire 05.16.13 | 08:05 am
- Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013 - PR Newswire 05.01.13 | 08:05 am
- Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference - PR Newswire 03.13.13 | 04:03 pm
- Depomed Provides Update On SEFELSAâ¿¢ FDA Advisory Committee - PR Newswire 03.04.13 | 01:03 pm
- Trading Of Depomed Common Stock Halted - PR Newswire 03.04.13 | 07:03 am
- Depomed To Present At Cowen And Company Health Care Conference - PR Newswire 02.26.13 | 04:02 pm
- Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013 - PR Newswire 02.13.13 | 04:02 pm
- Depomed Announces Appointment Of Vicente J. Anido, Jr., Ph.D. To Board Of Directors, And Retirement Of Directors Julian N. Stern And Craig R. Smith, M.D. - PR Newswire 02.11.13 | 08:02 am
- EmergingGrowth.com Special Report On RVPlus, Inc., Oil And Gas, And Patents Infringement In Pharmaceuticals - PR Newswire 12.28.12 | 08:12 am
- Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge - PR Newswire 12.26.12 | 04:12 pm
Partner Headlines for DEPO
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- Sell-Offs PROMPT Buying Opportunity for VF Corp. and 3 More Hot Analyst Alerts - Wall St. Cheat Sheet 06.21.12 | 03:06 am
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
